FDA approves dacomitinib for metastatic non-small cell lung cancer  

  RSS

Daniel
(@daniel)
New Member Admin
Joined: 3 years  ago
Posts: 212
05/11/2018 1:07 pm  

FDA approved dacomitinib tablets (VIZIMPRO, Pfizer Pharmaceutical Company) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. More Information.  September 27, 2018 


ReplyQuote
Share: